Updates on EPC, PCT, EPO case law and the e-EQE

The update of our EPC.App reference book to legal status of 1st November 2024 is completed. Key changes since the last update in April were the UPC ratification of Romania, new referral G 1/24, amended requirements for filing authorisations under Rule 152 and signing them, new entries on the list of representatives via MyEPO Portfolio, abolishment of Fax, legacy Mailbox and Myfiles, and updated ADA regulations.

In the self-editable online version of our EPC commentary, all changes of the update are rolled-out automatically, while personal user annotations from before the update are retained. They can be exported into a customized printable PDF offline version, which may further be ordered as colored paperback via the integrated print-on-demand service. As always, we also released this 13th edition in English and German with same content.

EP 3 167 888 B1 relates to the treatment of paroxysmal nocturnal hemoglobinuria patients with an inhibitor of complement component 5.
Claim 2 reads:
“A pharmaceutical composition comprising the antibody of claim 1.”
Claim 1 reads
“An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO: 2
and a light chain consisting of SEQ ID NO:4.”
According to the description SEQ ID NO: 2 represents the eculizumab heavy chain and SEQ ID NO:4 represents the eculizumab light chain.